Developmental Research Program

发展研究计划

• 批准号: 10268747
• 负责人: Meenhard F Herlyn
• 金额: $ 8.51万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-03 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10268747
• 关键词: Applications Grants; Cancer Center; Cancer Patient; Cutaneous Melanoma; Development; Ensure; Extramural Activities; Faculty; Fostering; Funding; Future; Goals; Grant; Measures; Monitor; Paper; Patient Care; Peer Review; Pilot Projects; Procedures; Process; Program Development; Progress Reports; Publications; Research; Research Personnel; Research Project Grants; Resources; Review Committee; Skin Cancer; Skin Carcinoma; The Wistar Institute; Underrepresented Minority; Woman; anticancer research; cancer research center director; expectation; high standard; interest; minority scientist; programs; recruit; research and development; research study; success

Project Summary – Developmental Research Program In the previous cycle, the Wistar/UPenn SPORE Development Research Program (DRP) was led by Dr. Robert Vonderheide, who has since become the Cancer Center Director of the Abramson Cancer Center. The DRP recruited a diverse array of investigators from many fields into melanoma and skin cancer research. The result has been an outstanding number of high impact papers, extramural grants, and two projects graduating from the DRP into full projects in this application. Building on this success, Dr. Meenhard Herlyn and Dr. Ravi Amaravadi, the co-Directors of this SPORE grant will serve as DRP co-Directors in the new cycle. The overall goals of the DRP in the new grant period remain to advance high quality research, foster new ideas, and move research studies from pilot to project status. A second goal of the DRP is to create opportunities for the scientific development of junior faculty or senior investigators who are interested in transitioning into skin cancer research. Our approach is summarized in 2 specific aims and is enabled by a strong commitment for an exceptional level of institutional support from The Wistar Institute and UPenn. The DRP will, in particular, welcome projects on non-melanoma skin cancers and topics not covered by the funded full Projects. Aim 1 is to attract, select and fund the most outstanding proposals with significant potential to benefit the Skin Cancer SPORE and translational skin cancer research. Specific research projects are summarized that represent all cancers of the skin. Aim 2 is to support and integrate the selected pilot projects into the SPORE program with established processes to review and monitor progress. Women and underrepresented minorities will be strongly encouraged to participate. The DRP has a transparent peer-reviewed selection process that incorporates defined criteria for funding decisions. We require that DRP awardees be active in SPORE functions, use the SPORE Core resource, and provide formal written progress reports. Within the context of the DRP, we have established high standards and expectations of the investigators and have established a formal process to review and monitor progress of funded pilot projects. The Program measures success by publications, extramural funding, stimulating new aims in existing SPORE Projects, and elevation to full projects for the future.

项目摘要——发展研究计划 在上一周期中，Wistar/UPenn SPORE 发展研究计划 (DRP) 由 Robert 博士领导 Vonderheide 自此成为艾布拉姆森癌症中心的癌症中心主任。 招募了来自多个领域的不同研究人员进行黑色素瘤和皮肤癌研究。 拥有大量高影响力的论文、校外资助和两个从该学院毕业的项目 在这一成功的基础上，Meenhard Herlyn 博士和 Ravi Amaravadi 博士将 DRP 融入到该应用程序的完整项目中。 该 SPORE 赠款的联合主任将在新周期中担任 DRP 联合主任。 新资助期内的 DRP 仍然致力于推进高质量研究、培育新思想和推动研究 从试点到项目状态的研究 DRP 的第二个目标是为科学创造机会。 培养对皮肤癌研究感兴趣的初级教师或高级研究人员。 我们的方法概括为 2 个具体目标，并通过对卓越水平的坚定承诺来实现 DRP 将特别欢迎威斯塔研究所和宾夕法尼亚大学的机构支持。 目标 1 是吸引、选择和资助的完整项目未涵盖的非黑色素瘤皮肤癌和主题。 资助最有潜力使皮肤癌孢子受益的最杰出的提案， 总结了代表所有癌症的具体研究项目。 目标 2 是支持选定的试点项目并将其整合到已建立的 SPORE 计划中。 将大力鼓励审查和监测进展情况的进程。 DRP 有一个透明的同行评审选择流程，其中包含了为参与而定义的标准。 我们要求 DRP 获奖者积极参与 SPORE 职能，使用 SPORE 核心资源， 并在 DRP 的范围内提供正式的书面进度报告，我们制定了高标准。 和调查人员的期望，并建立了一个正式的流程来审查和监测进展情况 该计划通过出版物、外部资金、刺激新目标来衡量成功与否。 在现有的 SPORE 项目中，并提升到未来的完整项目。